Immunity Against Measles in Korean Autologous Hematopoietic Stem Cell Transplant Recipients.

Autor:	Jang HM; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea., Bae S; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea., Jung J; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea., Cho H; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea., Yoon DH; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea., Kim SH; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. kimsunghanmd@hotmail.com.
Jazyk:	angličtina
Zdroj:	Journal of Korean medical science [J Korean Med Sci] 2024 Jul 22; Vol. 39 (28), pp. e224. Date of Electronic Publication: 2024 Jul 22.
DOI:	10.3346/jkms.2024.39.e224
Abstrakt:	The seropositivity of measles antibodies among 261 autologous stem cell transplant recipients (ASCTs) in Korea, assessed approximately 1-2 years after transplant (median, 11 months; interquartile range, 9-14), was significantly lower than age- and sex-matched control healthcare workers (83.1% [217/261] vs. 90.3% [539/597], P = 0.002). The findings underscore the vulnerability of adult ASCT recipients to measles. Clinicians should prioritize testing for measles IgG after ASCT and consider vaccination for ASCT recipients who remain seronegative 2 years after ASCT. Competing Interests: The authors have no potential conflicts of interest to disclose. (© 2024 The Korean Academy of Medical Sciences.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu